Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $98.6 million.

  • Viking Therapeutics' Operating Expenses rose 16961.65% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.8 million, marking a year-over-year increase of 10515.5%. This contributed to the annual value of $150.9 million for FY2024, which is 4968.31% up from last year.
  • As of Q3 2025, Viking Therapeutics' Operating Expenses stood at $98.6 million, which was up 16961.65% from $74.6 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Operating Expenses high stood at $98.6 million for Q3 2025, and its period low was $12.5 million during Q4 2021.
  • In the last 5 years, Viking Therapeutics' Operating Expenses had a median value of $23.7 million in 2023 and averaged $31.9 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 1104.21% in 2021, then surged by 16961.65% in 2025.
  • Over the past 5 years, Viking Therapeutics' Operating Expenses (Quarter) stood at $12.5 million in 2021, then surged by 62.13% to $20.3 million in 2022, then soared by 44.38% to $29.3 million in 2023, then skyrocketed by 57.89% to $46.2 million in 2024, then skyrocketed by 113.16% to $98.6 million in 2025.
  • Its Operating Expenses was $98.6 million in Q3 2025, compared to $74.6 million in Q2 2025 and $55.5 million in Q1 2025.